AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

Rhea-AI Summary

AIM ImmunoTech Inc. (AIM) announced the re-election of all three directors at its Annual Meeting of Shareholders. Directors Stewart Appelrouth, Thomas Equels, and William Mitchell received unanimous support. The company expressed gratitude towards shareholders and reaffirmed its commitment to advancing its lead drug, Ampligen, into oncology for long-term shareholder value. Ampligen is currently in clinical trials for various cancers and is approved in Argentina for chronic fatigue syndrome.

Positive

• All three directors re-elected, indicating strong shareholder support.
• Commitment to advancing Ampligen into oncology, potentially increasing long-term shareholder value.
• Ongoing clinical trials for Ampligen in various cancers may lead to future revenue growth.

Negative

• None.

OCALA, Fla.--(BUSINESS WIRE)-- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) held today.

AIM issued the following statement:

“We are grateful to our shareholders for their support and engagement. Going forward, we will continue our work to expand on our already significant progress in repurposing our lead drug, Ampligen, into oncology, and positioning the Company to deliver long-term value to shareholders.”

The results announced today have been tabulated and certified by the independent Inspector of Elections. The Company will file the final voting results on a Form 8-K with the Securities and Exchange Commission.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

Ampligen is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM has commenced a Phase 2 clinical study in 2022. The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. Additionally, Ampligen is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.

For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005865/en/

Investor:

JTC Team, LLC

Jenene Thomas

833-475-8247

AIM@jtcir.com

OR

Morrow Sodali

AIM@investor.MorrowSodali.com

Media:

Longacre Square Partners

Joe Germani / Dan Zacchei

jgermani@longacresquare.com / dzacchei@longacresquare.com

Source: AIM ImmunoTech Inc.

FAQ

What were the results of AIM ImmunoTech's Annual Meeting of Shareholders?

At the Annual Meeting, all three directors of AIM ImmunoTech were re-elected with unanimous support from shareholders.

What is AIM ImmunoTech's lead product?

AIM ImmunoTech's lead product is Ampligen, which is being developed for oncology and other diseases.

How is Ampligen currently being used in clinical trials?

Ampligen is being evaluated in multiple ongoing clinical trials for various solid tumor types and is approved for chronic fatigue syndrome in Argentina.

What is the significance of the re-election of AIM's directors?

The re-election signifies strong shareholder support and trust in the management's strategy for future growth.

When will AIM ImmunoTech file the final voting results of the Annual Meeting?

AIM will file the final voting results on a Form 8-K with the Securities and Exchange Commission.